Last Updated: April 2026 | Written by Fob James IV, J.D., Mass Tort Attorney | Fob James Law Firm, Birmingham, Alabama
Helping Alabama Patients Harmed by Dupixent (Dupilumab) Pursue Justice and Compensation
If you or a loved one in Alabama was prescribed Dupixent (dupilumab) and later developed cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides, or Sézary syndrome, you may have grounds to file a Dupixent lawsuit against the drug’s manufacturers, Sanofi and Regeneron Pharmaceuticals.
At Fob James Law Firm in Birmingham, Alabama, our mass tort attorneys represent clients across all 48 continental states in pharmaceutical injury claims. We have recovered over $100 million for more than 1,000 clients in defective drug and product liability litigation. We handle Dupixent cancer claims on a contingency fee basis — you pay nothing unless we win.
| IMPORTANT 2026 UPDATE: MDL Centralization Underway In February 2026, attorneys filed a motion before the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate all federal Dupixent CTCL cases into a single MDL. As of late March 2026, approximately 18 federal cases are pending nationwide, with the largest concentration in the Northern District of Georgia. The JPML’s decision on MDL formation is expected in mid-2026. Alabama clients can still file individual claims now — acting before MDL formation often results in stronger positioning. |
Quick Answers: Dupixent Lawsuit Alabama
| What is a Dupixent lawsuit? | A claim that Sanofi and Regeneron failed to warn patients that Dupixent could cause, accelerate, or unmask CTCL or PTCL. |
| Who can sue? | Dupixent users later diagnosed with CTCL, PTCL, mycosis fungoides, or Sézary syndrome. |
| Is there an MDL? | A motion to create a federal MDL was filed in February 2026. Individual cases are being filed now. |
| Alabama statute of limitations? | Generally 2 years from discovery of the link between Dupixent and your cancer diagnosis. |
| Cost to hire a lawyer? | Zero upfront. Fob James Law Firm is contingency-only — no fee unless we recover for you. |
| Contact? | Call 205-407-6009 or complete our online form for a free case evaluation. |
What Is Dupixent, and Why Are Patients Filing Lawsuits?
Dupixent (dupilumab) is an injectable biologic drug manufactured by Sanofi and Regeneron Pharmaceuticals. The FDA approved Dupixent in 2017, and its approved indications have since expanded to include:
- Moderate-to-severe atopic dermatitis (eczema)
- Certain types of asthma
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic esophagitis (EoE)
- Prurigo nodularis
- Chronic obstructive pulmonary disease (COPD)
Dupixent is a blockbuster drug. In 2025, it generated $18.3 billion in global sales — making it one of the highest-grossing pharmaceutical drugs on the market. Sanofi and Regeneron had powerful financial incentives to market Dupixent aggressively. Plaintiffs in Dupixent lawsuits allege this financial pressure contributed to the manufacturers’ failure to disclose a serious cancer risk to patients and prescribers.
The lawsuits center on one core allegation: Sanofi and Regeneron knew or should have known that Dupixent could cause, accelerate, or unmask cutaneous T-cell lymphoma in certain patients — and they failed to warn doctors or patients about this risk. Critically, as of April 2026, the word “lymphoma” does not appear anywhere in Dupixent’s FDA-approved prescribing label.
Why Choose Fob James Law Firm for Your Dupixent Lawsuit
When Dupixent (dupilumab) causes severe reactions, you need a legal team that understands the medical science behind your injuries. At Fob James Law Firm, our attorneys partner with board-certified dermatologists, immunologists, and allergy specialists to review your medical records and document the full extent of your Dupixent-related harm.
Why clients trust our Dupixent legal team:
- Comprehensive medical record evaluations by top specialists
- Deep experience in pharmaceutical and mass tort litigation
- Alabama-based team with real federal and state courtroom experience
- Backed by the power and resources of national drug-injury litigation
- Contingency fee representation — pay nothing unless we win
If you were harmed by Dupixent, we have the medical and legal firepower to fight for the compensation you deserve.
Cancers Linked to Dupixent: CTCL, PTCL, Mycosis Fungoides, and Sézary Syndrome
Two primary types of T-cell lymphoma have been associated with Dupixent use:
Cutaneous T-Cell Lymphoma (CTCL)
CTCL is a rare form of non-Hodgkin lymphoma involving malignant T-cells that migrate to the skin. In early stages, CTCL can be nearly indistinguishable from eczema or atopic dermatitis — the very condition Dupixent is prescribed to treat. This diagnostic overlap is central to the legal theory in most Dupixent lawsuits. By suppressing skin inflammation, Dupixent may mask the visible signs of an underlying cancer, delaying diagnosis until the disease has progressed to a more advanced, harder-to-treat stage.
The most common forms of CTCL include:
- Mycosis Fungoides — the most prevalent and slow-growing form, presenting as flat, scaly skin patches
- Sézary Syndrome — a more aggressive form that spreads to the blood and lymphatic system, causing widespread redness and immune dysfunction
- Primary cutaneous CD30+ T-cell lymphoproliferative disorders
- Extranodal NK/T-cell lymphoma
Peripheral T-Cell Lymphoma (PTCL)
In addition to CTCL, case reports and emerging litigation have linked Dupixent to peripheral T-cell lymphoma (PTCL) — a broader and often aggressive category of T-cell malignancy. In one reported case (the subject of a 2026 lawsuit filed in Illinois), a patient received only five Dupixent injections before developing swollen lymph nodes and receiving a PTCL diagnosis, requiring chemotherapy and a stem cell transplant. Our firm evaluates both CTCL and PTCL claims for Alabama residents.
Why Dupixent Makes CTCL So Difficult to Diagnose
The most insidious aspect of the Dupixent-CTCL link is the diagnostic gray zone between eczema and early-stage cutaneous T-cell lymphoma. Both conditions present with:
- Red, inflamed, itchy skin patches
- Scaly or crusted plaques
- Lichenification (thickened, leathery skin texture)
- Symptoms that flare and subside over time
- Partial response to topical steroids
Because eczema and early CTCL look nearly identical — even on biopsy in some cases — patients who actually have CTCL are regularly diagnosed with eczema and prescribed Dupixent. When Dupixent suppresses the visible inflammation, the improvement appears to confirm the eczema diagnosis. But if the underlying condition is CTCL, the cancer continues to advance beneath the surface. By the time the true diagnosis is made, patients are often at a more advanced and dangerous stage.
| What Plaintiffs Allege Sanofi and Regeneron Should Have Done: Warned prescribers that CTCL can mimic atopic dermatitis, especially in adults with treatment-resistant or atypical presentation. Recommended T-cell clonality testing or repeat skin biopsy before starting Dupixent in qualifying patients. Required monitoring and a “stop and investigate” protocol when a patient’s condition does not progress like typical eczema. Updated the prescribing label to include CTCL and PTCL risk information. None of these measures appear in the current Dupixent label. |
Scientific Evidence Cited in Dupixent Lymphoma Lawsuits
Multiple peer-reviewed studies and FDA adverse event data support the alleged link between Dupixent and T-cell lymphoma:
Large Database Studies
- JAMA Dermatology (April 2024): Analysis of 19,612 atopic dermatitis patients. Dupixent users showed 4.1x higher odds of developing CTCL (OR 4.1, 95% CI 2.1–8.2) compared to non-users. Risk persisted after adjustment; most diagnoses occurred more than one year after starting Dupixent.
- Dermatologic Therapy (August 2024): TriNetX study of 1.18 million AD patients. Dupixent linked to 4.6x higher relative risk of CTCL (RR 4.6, 95% CI 2.5–8.6). Highest risk in patients over 60 and within the first year of treatment.
- Journal of Allergy and Clinical Immunology (January 2025): FAERS and RNA-Seq analysis showing Dupixent had a 30x higher CTCL reporting rate compared to other medications. Proposed mechanism: IL-13 pathway suppression may accelerate malignant T-cell proliferation.
- European Respiratory Journal (June 2025): Population-based cohort of asthma patients (not atopic dermatitis) found Dupixent users faced 4.5x higher risk of CTCL compared to patients on standard inhaler therapy. This study extends the risk signal beyond eczema patients.
FDA Adverse Event Reporting System (FAERS)
- May 2025: An analysis of FAERS data found 181,575 total reports involving Dupixent. The rate of CTCL reports was approximately 30 times higher for Dupixent users compared to all other drugs in the database.
- As of October 2025: The FDA’s FAERS database contained nearly 300 lymphoma reports linked to Dupixent, including more than 138 CTCL-specific cases.
- March 2025: The FDA formally announced an investigation into Dupixent’s link to CTCL and placed the drug on a watch list for medications with potentially serious risks. The agency is evaluating whether new cancer warnings should be added to the label.
Case Series and Clinical Reports
- JAAD Case Reports (2022): Seven patients with severe atopic dermatitis developed or experienced worsening CTCL after starting Dupixent. Average time to CTCL diagnosis: 7.8 months. Biopsies showed unmasking of previously hidden lymphoma.
- International Journal of Dermatology (2023): Systematic review of 18 cases. All had more than 50% body surface involvement before diagnosis; advanced stages (III/IV) were common. Recommended biopsies 3–4 months post-initiation if no expected improvement.
- Blood Journal (November 2023): 25 patients at Memorial Sloan Kettering Cancer Center. Median time from Dupixent initiation to CTCL diagnosis: 10 months. Disease progression was often accelerated compared to non-Dupixent CTCL cases.
Warning Signs and Symptoms of Dupixent-Associated Lymphoma
If you have taken Dupixent and experience any of the following symptoms, consult your physician immediately. Do not stop or change your Dupixent use without medical guidance — but do request evaluation for lymphoma:
- New or worsening skin patches, plaques, or nodules that are scaly, itchy, or burning
- Persistent red or purple lesions that do not respond to eczema treatments as expected
- Thickened or tumorous skin areas, especially on sun-protected skin surfaces
- Swollen lymph nodes in the neck, armpits, or groin
- Unexplained weight loss, persistent night sweats, or recurring fevers (“B symptoms”)
- Eczema symptoms that initially improve then worsen in an unusual or atypical pattern
- Skin conditions that fail to behave as typical eczema over time
| Note: Only a qualified medical professional can diagnose T-cell lymphoma. The above symptoms do not confirm a cancer diagnosis. However, if you are on Dupixent and experience these symptoms, particularly if your condition is worsening or not improving as expected, prompt evaluation by a dermatologist or oncologist is critical. An Alabama Dupixent attorney at Fob James Law Firm can help you document the timeline of your symptoms and connect you with expert medical resources. |
Dupixent Lawsuit Status and Litigation Timeline (Updated April 2026)
| Date / Event | Update | Significance for Alabama Clients |
| 2017 | FDA approves Dupixent for moderate-to-severe atopic dermatitis. | Millions of patients begin using the drug; prescribers rely on label for safety information. |
| 2019 | Early case reports published in JAAD linking dupilumab to worsening or unmasking of CTCL. | Scientific community becomes aware of the eczema–CTCL diagnostic overlap risk. |
| April 2024 | JAMA Dermatology study: Dupixent users 4.1x more likely to develop CTCL vs. non-users. | Major peer-reviewed confirmation strengthens legal causation arguments. |
| Aug 2024 | TriNetX study: 4.6x higher relative risk of CTCL; highest in patients over 60. | Raises standard of care expectations for prescreening before initiating Dupixent. |
| Jan 2025 | JACI study: CTCL reporting rate 30x higher for Dupixent vs. other medications. | One of the most damaging data points for label adequacy claims. |
| March 2025 | FDA formally announces investigation into Dupixent’s cancer risk; drug placed on watch list. | FDA scrutiny bolsters failure-to-warn theory; no label update or recall yet. |
| May 2025 | FAERS analysis: 181,575 Dupixent reports; CTCL rate approximately 30x higher than all other drugs. | Demonstrates regulators had ample signal to require a label update years earlier. |
| June 2025 | ERJ study links Dupixent to 4.5x higher CTCL risk in asthma patients (not just eczema patients). | Expands universe of potential plaintiffs beyond eczema; risk signal not condition-specific. |
| Oct 2025 | First Dupixent wrongful death lawsuit filed in Tennessee. Patient died of T-cell lymphoma months after starting Dupixent. | Wrongful death claims expand potential damages and signal escalating litigation severity. |
| Feb 2026 | Levin Papantonio files motion before the JPML to transfer and consolidate all federal Dupixent CTCL cases into one MDL. Northern District of Georgia proposed as venue. | Alabama clients benefit from filing now — early filers often secure stronger case positioning in MDL proceedings. |
| Late Mar 2026 | Approximately 18 federal Dupixent cases pending nationwide. Both sides agree on MDL but disagree on venue. JPML ruling expected mid-2026. | MDL formation likely. Alabama clients should begin case review immediately to avoid statute of limitations issues. |
| April 2026 | Dupixent label still does not include a cancer warning. The word “lymphoma” does not appear anywhere in the prescribing information. | Core failure-to-warn claim remains intact and unaddressed by manufacturers. |
Legal Claims in a Dupixent Lawsuit
Dupixent lawsuits filed by patients and families allege that Sanofi and Regeneron:
- Failed to warn patients and prescribers about the risk of CTCL and PTCL, despite available evidence — the primary “failure to warn” theory under Alabama products liability law.
- Marketed Dupixent aggressively to maximize $18+ billion in annual revenue while suppressing or ignoring emerging cancer signals.
- Failed to require prescreening protocols (such as T-cell clonality testing or skin biopsy) in patients with adult-onset or treatment-resistant dermatitis before initiating Dupixent.
- Failed to include any protocol requiring physicians to “stop and investigate” when a patient’s symptoms do not follow the expected eczema progression pattern.
- Failed to update the Dupixent label despite receiving hundreds of adverse event reports to the FDA.
- In wrongful death cases: caused or substantially contributed to the death of patients whose CTCL or PTCL was delayed in diagnosis or accelerated by Dupixent use.
These claims arise primarily under product liability law — specifically failure-to-warn, design defect, and negligence theories — that apply under Alabama law and the laws of other states where clients reside.
Who Can File a Dupixent Lawsuit in Alabama?
You may be eligible to file a Dupixent injury lawsuit in Alabama if you meet the following criteria:
- You were prescribed Dupixent for an approved condition (eczema, asthma, nasal polyps, EoE, COPD, prurigo nodularis, or another indication).
- You were later diagnosed with cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides, Sézary syndrome, or another T-cell or NK-cell malignancy.
- Your cancer diagnosis occurred during or after your Dupixent treatment, or your pre-existing lymphoma was allegedly accelerated or unmasked by Dupixent.
- You have medical records — including pathology reports and treatment records — documenting both your Dupixent use and your cancer diagnosis.
- Your claim can be filed within Alabama’s statute of limitations (generally two years from discovery — see below).
Family members of Alabama patients who died from T-cell lymphoma linked to Dupixent may also have standing to file wrongful death claims. Contact our firm immediately to evaluate your specific situation.
What Compensation Can Alabama Dupixent Victims Recover?
Victims of Dupixent-related cancer injuries in Alabama may be entitled to recover:
- Medical expenses — past treatment costs (chemotherapy, radiation, stem cell transplants) and future care costs
- Lost wages and loss of future earning capacity
- Pain and suffering
- Emotional distress and psychological harm
- Loss of enjoyment of life
- Wrongful death damages — for family members of deceased victims, including funeral expenses, loss of consortium, and more
Each case is highly fact-specific. The strength of your medical evidence, the severity of your diagnosis, and the timing of Dupixent use all affect potential recovery. Our attorneys will evaluate your complete medical history during a free case review.
Alabama Statute of Limitations for Dupixent Drug Injury Claims
Under Alabama Code § 6-5-501 and related product liability statutes, most defective drug claims must be filed within two years of the date you discovered — or reasonably should have discovered — both the injury (your cancer diagnosis) and its connection to Dupixent.
This discovery rule is critical in Dupixent cases, because many patients did not learn of the alleged Dupixent-CTCL link until 2025 or later, when the FDA announced its formal investigation. If you were diagnosed with CTCL or PTCL years ago but only recently became aware of the Dupixent connection, you may still have time to file.
Do not wait. Statutes of limitations can be complex and are applied strictly in Alabama courts. Read our guide on how long you have to file a personal injury claim in Alabama for more background, or call Fob James Law Firm at 205-407-6009 today for a free case evaluation.
Steps to Take If You Used Dupixent and Were Diagnosed With Cancer
- Consult your physician before stopping Dupixent. Do not discontinue your medication without medical supervision.
- Request a complete copy of your medical records, including dermatology notes, pathology reports, and oncology treatment records.
- Document your timeline: when you started Dupixent, your dosage and frequency, when symptoms changed, and when you were diagnosed.
- Preserve all prescription records and pharmacy receipts related to Dupixent.
- Contact Fob James Law Firm at 205-407-6009 for a free, confidential case evaluation.
- Do not provide recorded statements to Sanofi, Regeneron, or their insurers without speaking to an attorney first.
Why Choose Fob James Law Firm for Your Alabama Dupixent Lawsuit?
- Alabama-based attorneys with real federal and state court experience in pharmaceutical and mass tort litigation
- Over $100 million recovered for 1,000+ clients in defective drug and injury claims
- Access to board-certified dermatologists, oncologists, and immunologists who review medical records and provide expert analysis
- Backed by national mass tort litigation resources — we have the infrastructure to take on Sanofi and Regeneron
- Contingency fee representation — you pay absolutely nothing unless we win your case
- Available to clients throughout Alabama, including Birmingham, Montgomery, Mobile, Huntsville, Tuscaloosa, and all surrounding counties
Frequently Asked Questions About Dupixent Lawsuits in Alabama
Is there a Dupixent recall in 2026?
No. As of April 2026, the FDA has not recalled Dupixent. The agency formally announced an investigation in March 2025 and continues to monitor adverse event reports of CTCL and other lymphomas. However, Dupixent remains on the market with no cancer warning on its label.
What cancers are linked to Dupixent?
The primary cancers linked to Dupixent are cutaneous T-cell lymphoma (CTCL) — including mycosis fungoides and Sézary syndrome — and peripheral T-cell lymphoma (PTCL). Emerging data also shows elevated risk of other T-cell and NK-cell malignancies.
Is there a Dupixent class action or MDL?
Dupixent lawsuits are not class actions. Each plaintiff’s case depends on individual medical history. In February 2026, plaintiffs’ attorneys filed a motion before the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate cases into a federal MDL. As of late March 2026, approximately 18 federal cases were pending. A JPML ruling on MDL formation is expected in mid-2026.
Can I file a Dupixent lawsuit if I live outside Alabama?
Yes. Fob James Law Firm represents Dupixent clients in 48 states. We are licensed in Alabama, Tennessee, and Georgia, and we co-counsel with qualified attorneys in other jurisdictions where required. Alabama residents always have local counsel available.
How long does a Dupixent lawsuit take?
Mass tort pharmaceutical cases typically take several years from filing to resolution. However, if an MDL is formed, bellwether trials and early settlements may occur within 2–3 years of centralization. Filing now rather than waiting preserves your claim and improves your positioning.
What is the statute of limitations for a Dupixent claim in Alabama?
In Alabama, the general statute of limitations for product liability claims is two years from the date you discovered — or reasonably should have discovered — both the injury and its connection to Dupixent. Because many patients only learned of the FDA’s 2025 investigation recently, the clock may have started running in 2025 for some. Contact our firm immediately to determine how the limitation period applies to your specific case.
What does it cost to hire a Dupixent lawyer at Fob James Law Firm?
Nothing upfront. We handle all Dupixent cases on a contingency fee basis. If we do not recover compensation for you, you owe us nothing. There are no out-of-pocket expenses to begin your case.
Is the Dupixent label defective?
Plaintiffs argue yes. As of April 2026, the FDA-approved Dupixent prescribing information does not mention cutaneous T-cell lymphoma, peripheral T-cell lymphoma, mycosis fungoides, Sézary syndrome, or the word “lymphoma” at all — despite hundreds of adverse event reports and multiple peer-reviewed studies establishing a statistical association.
Can the family of someone who died from Dupixent-linked lymphoma file a lawsuit?
Yes. Family members of patients who died from CTCL or PTCL allegedly linked to Dupixent may be able to file a wrongful death lawsuit in Alabama. The first Dupixent wrongful death lawsuit was filed in Tennessee in October 2025. Contact Fob James Law Firm to evaluate your family’s legal options.
I was prescribed Dupixent for asthma, not eczema. Can I still sue?
Potentially yes. A June 2025 study published in the European Respiratory Journal found that Dupixent users with asthma — not atopic dermatitis — faced a 4.5x higher risk of CTCL compared to patients on other asthma medications. The cancer risk signal is not limited to eczema patients.
How do I start a Dupixent claim in Alabama?
Call our Birmingham office at 205-407-6009 or complete our online case evaluation form at callfob.com/contact. Our legal team will review your medical history, explain your rights under Alabama law, and guide you through every step of the process — at no charge until we win.
Contact an Alabama Dupixent Lawsuit Lawyer Today — Free Consultation
If you or a family member developed T-cell lymphoma, CTCL, PTCL, mycosis fungoides, or Sézary syndrome after taking Dupixent, don’t wait. Every day you delay could affect your statute of limitations and your ability to recover compensation.
Call Fob James Law Firm at 205-407-6009 or complete our online form for a free, confidential case evaluation. We serve clients throughout Alabama, including Birmingham, Montgomery, Mobile, Huntsville, Tuscaloosa, and every surrounding county. We represent clients nationwide in 48 states.
Our Dupixent lawsuit lawyers are ready to fight for your rights and hold Sanofi and Regeneron accountable.